Literature DB >> 29332231

Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol.

Luca Ramaglia1, Agostino Guida1, Vincenzo Iorio-Siciliano1, Alessandro Cuozzo1, Andrea Blasi1, Anton Sculean2.   

Abstract

OBJECTIVE: The most debated topic about medication-related osteonecrosis of the jaws (MRONJ) is its therapy, as there are no definitive guidelines. The aims of this systematic review were (a) to outline the best therapeutic approach according to the stage at diagnosis and (b) to perform a meta-analysis to assess whether the drug-holiday protocol may be or not an effective method in the management of MRONJ patients.
MATERIALS AND METHODS: The systematic review was performed following the PRISMA principles. Results were screened according to inclusion and exclusion criteria regarding staging before/after treatment, follow-up, and information provided by the authors. For statistical analysis, linear variables are reported as means and standard deviations, medians, and inter-quartile range (IQR); normality of data, according to the distribution of complete healing (primary outcome variable), was assessed with the Kolmogorov-Smirnov test. A p value < 0.05 was considered statistically significant for all tests.
RESULTS: Thirteen studies were selected out of 1480. None of them was case-controlled or randomized. Conservative approach showed good results at early stages, but heterogeneous result at advanced stages (100% stage 0, stage I range 81-97%, stage II range 63.6-100%, stage III 73%). Surgical approach showed heterogeneous results at all stages (stage I range 0-100%, stage II range 52-100%, stage III range 50-100%). Statistical analysis showed a significantly higher prevalence of completely healed sites in patients who followed the drug-holiday protocol.
CONCLUSIONS: The results suggest that the current stage-specific approach for MRONJ therapy is based on a sound clinical rationale. Conservative treatment appears to yield better outcomes at early stages, while further investigations are needed to elucidate the best protocols for the management of advanced stages. The drug-holiday protocol statistically promotes complete healing after oral surgery procedures but the application should be dictated by the condition of each patient. CLINICAL RELEVANCE: At present, early MRONJ stages should be primarily treated by means of a conservative approach while more advanced stages must be carefully evaluated. Individual decisions should be made for every single case even with respect to the drug-holiday protocol.

Entities:  

Keywords:  ARONJ; BRONJ; Bisphosphonates; Drug-holiday protocol; MRONJ; Osteonecrosis

Mesh:

Substances:

Year:  2018        PMID: 29332231     DOI: 10.1007/s00784-017-2325-6

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  54 in total

1.  A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws.

Authors:  Filippo Moretti; Gian Andrea Pelliccioni; Lucio Montebugnoli; Claudio Marchetti
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2011-10-14

2.  Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw.

Authors:  S Bocanegra-Pérez; M Vicente-Barrero; M Knezevic; J M Castellano-Navarro; E Rodríguez-Bocanegra; J Rodríguez-Millares; D Pérez-Plasencia; A Ramos-Macías
Journal:  Int J Oral Maxillofac Surg       Date:  2012-05-28       Impact factor: 2.789

3.  A decade of bisphosphonate bone complications: what it has taught us about bone physiology.

Authors:  Robert E Marx
Journal:  Int J Oral Maxillofac Implants       Date:  2014 Mar-Apr       Impact factor: 2.804

4.  Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giuseppe Avvisati; Giordano Dicuonzo; Fabrizio Battistoni; Michele Gavasci; Alfredo Salerno; Vincenzo Denaro; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

5.  Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases.

Authors:  Sebastiano Ferlito; Sergio Puzzo; Filippo Palermo; Placido Verzì
Journal:  Br J Oral Maxillofac Surg       Date:  2011-09-09       Impact factor: 1.651

6.  Surgical management of bisphosphonate induced osteonecrosis of the jaws.

Authors:  R A Williamson
Journal:  Int J Oral Maxillofac Surg       Date:  2009-12-16       Impact factor: 2.789

7.  Bisphosphonate-associated osteonecrosis of the jaw. A proposal for conservative treatment.

Authors:  Sacramento Bocanegra Pérez; Mario Vicente Barrero; Manuel Sosa Hernández; Milan Knezevic; José María Castellano Navarro; José Rodríguez Millares
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2008-12-01

8.  Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.

Authors:  Tae min You; Kang-Hee Lee; Soo-Hyeon Lee; Wonse Park
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2015-07-22

9.  Disease Stage and Mode of Therapy Are Important Determinants of Treatment Outcomes for Medication-Related Osteonecrosis of the Jaw.

Authors:  Salvatore L Ruggiero; Nina Kohn
Journal:  J Oral Maxillofac Surg       Date:  2015-12       Impact factor: 1.895

10.  Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw.

Authors:  Paolo Vescovi; Elisabetta Merigo; Marco Meleti; Maddalena Manfredi; Carlo Fornaini; Samir Nammour; Giovanni Mergoni; Amin Sarraj; Jose V Bagan
Journal:  Int J Dent       Date:  2014-02-06
View more
  24 in total

1.  Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws.

Authors:  Elisabetta Merigo; Luigi Cella; Aldo Oppici; Maria Cristina Arbasi; Fabio Clini; Matteo Fontana; Carlo Fornaini
Journal:  J Lasers Med Sci       Date:  2018-03-20

2.  The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.

Authors:  Meltem Ozden Yüce; Emine Adalı; Gözde Işık
Journal:  Clin Oral Investig       Date:  2021-01-03       Impact factor: 3.573

3.  Volumetric analysis of the periodontal microstructure under antiresorptive therapy: an experimental study in rabbits.

Authors:  Kathrin Becker; Robert Kerberger; Giulia Brunello; Joel Rockhoff; Nicole Rauch; Frank Schwarz
Journal:  Clin Oral Investig       Date:  2022-04-22       Impact factor: 3.606

4.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

5.  Morphological and immunohistochemical features of tooth extraction sites in rats treated with alendronate, raloxifene, or strontium ranelate.

Authors:  Valesca Sander Koth; Fernanda Gonçalves Salum; Maria Antonia Zancanaro de Figueiredo; Karen Cherubini
Journal:  Clin Oral Investig       Date:  2020-09-23       Impact factor: 3.573

6.  Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value.

Authors:  Ruri Ogawa; Ichiro Ogura
Journal:  Dentomaxillofac Radiol       Date:  2021-05-21       Impact factor: 2.419

7.  Small Extracellular Vesicles Derived from Adipose Tissue Prevent Bisphosphonate-Related Osteonecrosis of the Jaw by Promoting Angiogenesis.

Authors:  Jiao Huang; Lin Wang; Weidong Tian
Journal:  Int J Nanomedicine       Date:  2021-05-07

8.  Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.

Authors:  Shruthi Acharya; Vathsala Patil; Vineetha Ravindranath; Adarsh Kudva; Krithi Nikhil
Journal:  J Med Life       Date:  2022-03

Review 9.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

10.  Use and Evaluation of a Computer-Assisted Examination Method for the Diagnosis and Analysis of Medication-Related Osteonecrosis of the Jaw.

Authors:  Max Wilkat; Daman Deep Singh; Isabelle Lutz; Henriette Möllmann; Nils-Claudius Gellrich; Majeed Rana
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2020-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.